Healthcare CMO Market To Surpass US$ 1,861.2 Million By 2033

Introduction

The Global Healthcare CMO Market size is expected to be worth around US$ 1,861.2 Million by 2033 from US$ 436.7 Million in 2023, growing at a CAGR of 16.6% during the forecast period from 2024 to 2033. In 2023, North America led the market, achieving over 42.5% share with a revenue of US$ 185.5 Million.

The outsourcing market within the global pharmaceutical and biotechnology industry has emerged as one of the fastest-growing sectors, with contract manufacturing for pharmaceutical and medical devices holding a significant share. Traditionally, the pharmaceutical and medical device industries exhibited a low level of outsourcing due to concerns over product quality, delivery delays, regulatory compliance, and intellectual property protection.

In recent years, however, outsourcing has become increasingly attractive as pharmaceutical and medical device companies pursue strategies to reduce costs, expand product portfolios, accelerate time-to-market, and improve operational efficiency. Furthermore, economic challenges, financial crises, and technological advancements have prompted pharmaceutical, biotechnology, and life sciences companies to outsource manufacturing processes for cost savings and time efficiency.

The global healthcare CMO market is segmented into pharmaceutical contract manufacturing services and medical devices contract manufacturing services. Pharmaceutical contract manufacturing services are further divided into API (active pharmaceutical ingredients) manufacturing, FDF (final dosage formulations) manufacturing, and packaging.

The FDF contract manufacturing segment is projected to witness robust growth from 2024 to 2033, driven by increasing demand for generic drugs and heightened R&D investments by life sciences companies. This growth is further fueled by the expiration of patents on blockbuster drugs and the adoption of advanced technologies. Similarly, the medical devices contract manufacturing services segment is categorized into design outsourcing, device manufacturing, and final goods assembly.

Key Takeaways

• Market Size: Healthcare CMO Market size is expected to be worth around US$ 1,861.2 Million by 2033 from US$ 436.7 Million in 2023
• Market Growth: The market growing at a CAGR of 16.6% during the forecast period from 2024 to 2033.
• Service Analysis: By service segment, Pharmaceutical Contract Manufacturing Services have an outstanding 62.0% share in the Healthcare CMO market analysis.
• Regional Analysis: By Regional Analysis, North America domenate 42.5% market share and holding approx USD 185.5 Million revenue in 2023.
• Outsourcing Demand: Increasing demand for cost-efficient manufacturing solutions and technological advancements are driving the growth of the outsourcing market in the pharmaceutical and medical device industries.
• Strategic Shifts: Companies are adopting outsourcing strategies to reduce costs, improve product portfolios, accelerate time-to-market, and enhance operational efficiencies.
• Pharmaceutical Focus: The FDF manufacturing segment is expected to see significant growth due to the rising demand for generic drugs and increased R&D investment.
• Drivers of Growth: Economic pressures, financial crises, and the need to adopt novel technologies are compelling companies to outsource their manufacturing processes.
• Medical Devices Segment: The medical devices contract manufacturing services segment includes design outsourcing, device manufacturing, and final goods assembly, reflecting the diverse needs of the industry.
• Regulatory and Quality Concerns: While historically a concern, regulatory compliance, product quality, and intellectual property protection are increasingly being managed effectively by CMOs, making outsourcing a more attractive option.

Healthcare (CMO) Market Statistics

• National Health Expenditure (NHE): NHE is forecasted to grow at an average rate of 5.6% annually from 2023 to 2032, raising its GDP share from 17.3% in 2022 to 19.7% by 2032.
• Medicare Spending: Medicare expenditures are projected to grow at an average annual rate of 7.4% from 2023 to 2032.
• Medicaid Spending: Medicaid spending is expected to increase at an average rate of 5.2% per year over the same period.
• Private Health Insurance: Private health insurance spending is anticipated to grow at an annual rate of 5.6% from 2023 to 2032.
• Out-of-Pocket Spending: Out-of-pocket healthcare expenses are projected to grow at an average annual rate of 4.7% during this period.
• Hospital Expenditures: Hospital spending is expected to increase at an average annual rate of 5.7% from 2023 to 2032.
• Physician and Clinical Services: Spending on physician and clinical services is projected to grow at an average rate of 5.6% annually from 2023 to 2032.
• Prescription Drug Spending: Retail prescription drug spending is forecasted to grow at an average annual rate of 6.0% between 2023 and 2032.
• Medicaid Enrollment: Medicaid enrollment reached a record 91.2 million in 2023 and is expected to stabilize post-2024.
• Insurance Coverage: The insured population in the U.S. reached a historic high of 93.1% in 2023.
• Health Price Growth: Health price growth remained modest at 2.5% in 2023, higher than pre-pandemic levels.
• Hospital EHR Adoption: By 2021, 96% of non-federal acute care hospitals had adopted certified electronic health records (EHRs).
• Telehealth Utilization: Telehealth visits increased by 200% between 2019 and 2023, reflecting a surge in digital health adoption.
• Marketplace Enrollment: HealthCare.gov Marketplaces saw a 19% increase in plan selections for 2023, reaching 12.2 million enrollees.

Company Analysis

• Accellent, Inc: In April 2024, Accellent acquired Medical Manufacturing Innovations (MMI) to strengthen its capabilities in precision medical device components. This acquisition aims to enhance product quality and accelerate time-to-market for complex medical devices, meeting rising healthcare demands.
• Boehringer Ingelheim GmbH: In May 2024, Boehringer launched BioXpress, a rapid biologics development platform designed to expedite monoclonal antibody and recombinant protein production, addressing growing oncology and immunology needs.
• Catalent Pharma Solutions, Inc: In March 2024, Catalent merged with Biotech Innovations, integrating advanced gene therapy manufacturing technologies to speed up the development and commercialization of gene therapies and offer comprehensive biotechnology solutions.
• Lonza Group: In February 2024, Lonza acquired CellMed Therapeutics to expand its cell and gene therapy manufacturing services, enhancing its ability to support early development through commercial production and solidifying its biopharmaceutical industry position.
• Patheon, Inc.: In January 2024, Patheon launched PharmaFlex, a flexible manufacturing platform for biologics, small molecules, and complex formulations. This platform uses modular cleanrooms and automation to boost efficiency and reduce time-to-market.
• Piramal Healthcare: In June 2024, Piramal merged with Advanced BioSolutions to combine expertise in pharmaceutical manufacturing and bioprocessing technologies. This move enhances Piramal’s biopharmaceutical production capabilities and broadens its biologics and biosimilars offerings.

Emerging Trends

• Market Growth: The global healthcare CMO market is projected to grow from USD 436.7 million in 2023 to USD 1,861.2 million by 2033, at a CAGR of 16.6%.
• Outsourcing Surge: Outsourced pharmaceutical and medical device manufacturing saw a 30% rise in contracts in 2023, reflecting a growing reliance on CMOs.
• Regulatory Standards: Over 85% of CMOs adhere to international quality standards, improving regulatory compliance and increasing their appeal to pharmaceutical companies.
• Technological Advancements: By 2023, 60% of CMOs adopted AI-driven manufacturing processes, improving efficiency and product quality through automation.
• Cost Management: Economic pressures have led pharmaceutical companies to reduce manufacturing costs by up to 25% through outsourcing.
• R&D Investments: Pharmaceutical R&D spending grew by 14% in 2023, boosting demand for CMOs to support development processes.
• IP Protection: Stringent intellectual property policies are now in place at 90% of CMOs, addressing a key concern for pharmaceutical companies.
• Off-Patent Drugs: The number of blockbuster drugs losing patent protection is driving demand for generic drug manufacturing, with 20 major drugs expected off-patent by 2025.
• Specialized Services: Design outsourcing and final goods assembly are growing annually by 18% and 20%, respectively, particularly in the medical device segment.
• Digital Health: Telehealth usage increased by 200% between 2019 and 2023, highlighting the importance of digital health trends.
• Sustainability: Over 70% of CMOs are implementing greener technologies to reduce environmental impacts and promote sustainable manufacturing.
• Regional Growth: North America led the healthcare CMO market with a 45% share in 2023, with strong growth observed in Europe and Asia-Pacific.

Use Cases

• Drug Development: CMOs support pharmaceutical companies from preclinical trials to commercial production, ensuring efficient new drug market entry.
• API Manufacturing: CMOs play a critical role in producing high-quality Active Pharmaceutical Ingredients (APIs), a segment poised for growth due to rising drug demand.
• Biologics Production: CMOs are instrumental in producing biologics such as monoclonal antibodies and recombinant proteins, essential in treating various diseases.
• Specialized Manufacturing: They offer niche capabilities for orphan drugs and rare diseases, enabling small-batch, high-cost drug production.
• Generic Drug Manufacturing: With patents expiring on blockbuster drugs, CMOs help meet the growing demand for cost-effective generic medications.
• Medical Devices: CMOs provide comprehensive manufacturing solutions for medical devices, including implants and diagnostic equipment, from design to final assembly.
• Regulatory Compliance: CMOs ensure adherence to stringent global regulatory requirements, simplifying compliance for pharmaceutical companies.
• Supply Chain Management: CMOs manage logistics, inventory, and distribution, ensuring timely production and delivery of pharmaceutical products.
• Scalability: CMOs offer scalable manufacturing to adjust production volumes based on market demand, providing flexibility to pharmaceutical companies.
• Cost Efficiency: By outsourcing to CMOs, companies reduce capital expenses on facilities and equipment, reallocating resources to research and development.

Conclusion

The outsourcing market within the global pharmaceutical and biotechnology industries is experiencing rapid growth, driven by cost reduction strategies, accelerated time-to-market needs, and increasing demand for operational efficiency.

With a projected CAGR of 16.6% from 2024 to 2033, the global healthcare CMO market is expected to expand from USD 436.7 million in 2023 to USD 1,861.2 million by 2033. Pharmaceutical contract manufacturing dominates, particularly in FDF manufacturing, fueled by patent expirations and rising generic drug demand.

Medical device outsourcing is also growing, led by design and final assembly services. Companies are leveraging CMOs to enhance product quality, scalability, and compliance with regulatory standards. Advanced technologies, increased R&D investments, and sustainability initiatives further reinforce the market’s potential, with North America leading regional growth and Asia-Pacific emerging as a key contributor.

Discuss your needs with our analyst

Please share your requirements with more details so our analyst can check if they can solve your problem(s)

Request a Sample Download PDF